argenx applies a unique suite of technologies to develop human antibody therapeutics against disease targets that are underserved in the biotherapeutic space. Combining our technology strengths with our antibody development capabilities and the complementary skills of our scientists enables us to create highly differentiated antibody programs for both our wholly-owned pipeline and in collaboration with our partners.

argenx’ antibody discovery platform, SIMPLE Antibody™, delivers human antibodies with distinctive therapeutic qualities against the most challenging disease targets. With the power to break into unchartered target territory, we go beyond the boundaries of traditional antibody technologies. In addition to the strengths of SIMPLE Antibody™, our state-of-the-art capabilities in Fc engineering (NHance™, ABDEG™ and POTELLIGENT®) create antibody programs with first and/ or best-in-class therapeutic potential.